目的：观察埃克替尼用于治疗晚期肺腺癌患者的疗效及安全性,分析影响其疗效的相关因素方法回顾性分析在江苏省肿瘤医院慈善赠药点接受埃克替尼治疗90例晚期肺腺癌患者的临床资料。结果可评价疗效的90例患者中完全缓解(CR)0例,部分缓解(PR)55例(61.1%),疾病稳定(SD)28例(31.1%),疾病进展(PD)7例(7.8%),客观缓解率(ORR)为61.1%,疾病控制率(DCR)为92.2%。90例患者中位无进展生存期(PFS)为10.5(1.3~22.3)个月。已知EGFR突变阳性的40例患者中CR 0例,PR 28例(70.0%),SD 12例(30.0%)。 ORR为70.0%,DCR为100%。结论埃克替尼治疗晚期肺腺癌具有显著的疗效和良好的安全性。%Objective To evaluate the efficacy and toxicity of icotinib,and to analyze prognostic factors influencing curative effect in patients with advanced non-small cell lung adenocarcinoma. Methods The clinical data of 90 non-small cell lung adenocarcinoma pa-tients referred to the Jiangsu Cancer Hospital were retrospectively analyzed. Results All patients were evaluable for efficacy. Among the 90 patients,there was none with complete response(CR),55 patients with partial response (PR,61. 1%),28 patients with stable disease (SD,31. 1%) and 7 patients with progression disease (PD,7. 8%). The objective response rate (ORR) was 61. 1%,and the disease control rate (DCR) was 92. 2%. The total progressive free survival was 10. 5 (1. 3~22. 3) months. Among the 40 patients with EGFR mutations,there was none with CR,28 patients with partial response ( PR,70. 0%),12 patients with stable disease ( SD, 30. 0%). The objective response rate (ORR) was 70. 0%,and the disease control rate (DCR) was 100%. Conclusions Icotinib is effective and safe in patients with advanced non-small cell lung adenocarcinoma.
展开▼
